ReviewRNA biology2026
Crosstalk between circRNAs and the classic signaling pathways in IBD.
Review in RNA biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disorder of the gastrointestinal tract with a complex aetiology involving genetic, environmental (such as diet/lifestyle), and microbiota factors. The exact pathogenesis of IBD remains unclear, and current therapies show limited effectiveness. Circular RNAs (circRNAs) are a novel class of noncoding RNAs that have been implicated in the regulation of various biological processes. Many circRNAs show specific expression profiles in IBD patients and play important roles in IBD pathogenesis through different signalling pathways, such as the Janus kinase/signal transducer and activator of transcription (JAK/STAT) and nuclear factor-κB (NF-κB) pathways. Although research on circRNAs in IBD is still in its early stages, many circRNAs have emerged as potential diagnostic, prognostic biomarkers, and therapeutic targets for IBD. Here, we summarize the molecular functions and underlying mechanisms of circRNAs in IBD and discuss current challenges and future perspectives for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.